Ibisobanuro bigufi:
Ingano: 000 #, 00 #, 0 #, 1 #, 2 #, 3 #
| Amakuru Yibanze | |
| Izina ryibicuruzwa | Alpha-lipoic aside Ikomeye ya Capsule |
| Andi mazina | Lipoic aside Capsule, ALA Ikomeye,α- L.acide ipoicCapsule ikomeye nibindi |
| Icyiciro | Urwego rwibiryo |
| Kugaragara | Nkibisabwa nabakiriya000 #, 00 #, 0 #, 1 #, 2 #, 3 # |
| Ubuzima bwa Shelf | 2-3years, ukurikije imiterere yububiko |
| Gupakira | Nkibisabwa abakiriya |
| Imiterere | Bika mu bikoresho byoroshye, birinzwe n'umucyo. |
Ibisobanuro
Alpha-lipoic aside ni urugingo ngengabuzima ruboneka mu ngirabuzimafatizo zose z'abantu.
Ikozwe muri mitochondrion - izwi kandi nk'imbaraga za selile - aho ifasha imisemburo guhindura intungamubiri imbaraga.
Ikirenzeho, ifite antioxydants ikomeye.
Acide ya Alpha-lipoic ni amazi- hamwe no gushonga ibinure, ituma ikora muri buri selile cyangwa tissue mu mubiri. Hagati aho, izindi antioxydants nyinshi ni amazi- cyangwa ibinure.
Indwara ya antioxydeant ya acide alpha-lipoic yahujwe ninyungu nyinshi, zirimo isukari nke mu maraso, kugabanya umuriro, gutinda gusaza kwuruhu, no kunoza imikorere yimitsi.
Abantu bakora aside alpha-lipoic gusa muke. Niyo mpamvu benshi bahindukirira ibiryo cyangwa inyongeramusaruro kugirango bahuze neza.
Imikorere
Kugabanuka
Ubushakashatsi bwerekanye ko aside alpha-lipoic ishobora kugira ingaruka ku kugabanuka muburyo butandukanye.
Diyabete
ALA irashobora gufasha mukurwanya glucose mukwihutisha metabolisme yisukari yamaraso. Ibi birashobora gufasha gucunga diyabete, indwara irangwa n'amaraso menshi ya glucose.
Birashobora kugabanya gusaza k'uruhu
Ubushakashatsi bwerekanye ko aside alpha-lipoic ishobora gufasha kurwanya ibimenyetso byo gusaza kwuruhu.
Byongeye kandi, aside alpha-lipoic izamura urwego rwizindi antioxydants, nka glutathione, ifasha kurinda kwangirika kwuruhu kandi bishobora kugabanya ibimenyetso byubusaza.
Gicurasi gutinda kwibuka
Kubura kwibuka nibisanzwe mubantu bakuze.
Kubera ko aside alpha-lipoic ari antioxydants ikomeye, ubushakashatsi bwasuzumye ubushobozi bwayo bwo kudindiza iterambere ryimivurungano irangwa no guta umutwe, nkindwara ya Alzheimer.
Ubushakashatsi bwakozwe n'abantu ndetse na laboratoire bwerekana ko aside alpha-lipoic idindiza iterambere ry’indwara ya Alzheimer itesha agaciro radicals yubuntu no guhagarika umuriro.
Guteza imbere imikorere myiza yimitsi
Ubushakashatsi bwerekanye ko aside alpha-lipoic iteza imbere imikorere myiza yimitsi.
Mubyukuri, wasangaga bidindiza iterambere rya syndrome ya carpal mubyiciro byayo byambere. Iyi miterere irangwa no kunanirwa cyangwa gutitira mu ntoki biterwa n'umutima ucuramye.
Byongeye kandi, gufata aside alpha-lipoic mbere na nyuma yo kubagwa syndrome ya carpal tunnel byagaragaye ko bizamura umusaruro.
Ubushakashatsi bwerekanye kandi ko aside alpha-lipoic ishobora koroshya ibimenyetso bya neuropathie diabete ya diabete, ikaba ari ububabare bw’imitsi iterwa na diyabete itagenzuwe.
Kugabanya gucana
Indurwe idakira ifitanye isano n'indwara nyinshi, harimo kanseri na diyabete.
Alpha-lipoic aside yerekanwe kugabanya ibimenyetso byinshi byo gutwika.
Birashobora kugabanya indwara ziterwa numutima
Ubushakashatsi bwakozwe na laboratoire, inyamaswa, n’ubushakashatsi bw’abantu bwerekanye ko antioxydeant ya aside alpha-lipoic aside ishobora kugabanya ibintu byinshi bishobora gutera indwara z'umutima.
Icya kabiri, byerekanwe kunoza imikorere mibi ya endoteliyale - imiterere imiyoboro yamaraso idashobora kwaguka neza, nayo itera ibyago byo gutera umutima no guhagarara k'umutima.
Ikirenze ibyo, ubushakashatsi bwakozwe bwerekanye ko gufata aside ya alpha-lipoic yagabanije triglyceride na LDL (mbi) ya cholesterol ku bantu bakuru bafite uburwayi bwa metabolike.
Na Ryan Raman, MS, RD
Porogaramu
1. Abantu bafite ibimenyetso byindwara ya diabete ya diabete nko kunanirwa ingingo, kubabara, nuruhu rwijimye;
2. Abantu bakeneye kugenzura isukari;
3. Abantu babungabunga ubuzima bwimitsi yumutima;
4. Abantu bakeneye gufata umwijima;
5. Kurwanya gusaza, kurwanya gusaza;
6. Abantu bakunda umunaniro nubuzima buke;
7. Abantu bakunze kunywa inzoga bakarara.
